ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

DLL3

delta like canonical Notch ligand 3 · also SCDO1 · Canonical Notch ligands

16 programs in company-led studies act on DLL3, from 14 companies: 6 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
tarlatamabruleAmgen–phase 31312 runningCD3ENCIt
AlveltamigruleSuzhou Zelgen Biopharmaceuticals–phase 31111 runningCD3ENCIt
obrixtamigBoehringer Ingelheim–phase 31111 runningCD3Ethe company's pipeline
Zocilurtatug PelitecanruleZai Lab–phase 366 running–NCIt
Anti-DLL3 Antibody-drug Conjugate BL-M14D1Sichuan Biokin Pharmaceutical–phase 344 running–the company's pipeline
gocatamigMerck–phase 344 runningCD3Ea judged reading
Anti-DLL3 Antibody-drug Conjugate IDE849IDEAYA Biosciences–phase 222 running–the company's pipeline
Autologous Anti-DLL3 CAR-T Cells DJI136Novartis–phase 222 running–the company's pipeline
SHR-7787Jiangsu HengRui Medicine–phase 211 runningCD3Ethe company's pipeline
Anti-DLL3 Antibody-drug Conjugate FZ-AD005ruleShanghai Fudan-Zhangjiang Bio-Pharmaceutical–phase 122 running–NCIt
clesitamigHoffmann-La Roche–phase 121 runningCD3E, TNFRSF9a judged reading
Actinium Ac 225-ABD147ruleAbdera Therapeutics–phase 111 running–NCIt
Actinium Ac 225-ETN029Novartis–phase 111 running–the company's pipeline
Autologous Anti-DLL3 CAR/CARD11-PIK3R3 Fusion Transgene-expressing T-cells ML261ruleMoonlight Bio–phase 111 runningCARD11, PIK3R3NCIt
HLX3901Fosun Pharma–phase 111 runningCD28, CD3Ethe company's pipeline
Indium In 111-ETN029Novartis–phase 111 running–the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.